← Back to Knowledge Base

Primary topic: PPARA fat metabolism gene

PPARA Gene and Metabolism: What It Means for Your Body

PPARA helps regulate fat oxidation, especially when the body is shifting toward using stored fat for energy.

What is the PPARA gene?

PPARA is a nuclear receptor that influences how genes involved in fatty acid transport and oxidation are expressed. It becomes especially relevant during fasting, endurance demand, and broader lipid metabolism.

How PPARA affects metabolism

If PPARA-related signaling is less efficient, the body may be slower to rely on fat as a fuel source under certain conditions. That can show up as weaker metabolic flexibility, less efficient lipid handling, or a mismatch between fasting expectations and actual energy response.

What happens when PPARA is altered

Altered PPARA function does not automatically create disease, but it can reduce how smoothly fat-use pathways respond when the body is meant to lean on them more heavily.

Curated SNP evidence for PPARA

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Lipids

Evidence-backed report connection

PPARA currently has 2 curated SNPs, 6 claim-level scores, and 0 claims eligible for pathway scoring.

Open the sample report
rs1800206L162V3 claims · 12 study rows

expression · CG

PPARA gene expression

Not used for pathway scoring

rs1800206 CG is associated with reduced PPARA gene expression.

PPARA rs1800206 is scored as a lower PPAR-alpha transcriptional-response tendency for G-containing genotypes, with stronger scoring for GG than CG.

Likely effectLower gene expression signal
Signal sizeSmall signal
Evidence supportLimited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs1800206 in PPARA and annotate it as a coding variant that can be missense in relevant transcripts. The common studied change is PPARA L162V, with the G allele corresponding to the V162 form in the cited functional studies.PubMed 19266045functional assay · loose proxyRudkowska et al. compared the L162 and V162 PPAR-alpha forms in HepG2 cell assays after omega-3 fatty acid treatment. Both forms responded to omega-3 fatty acids, but the V162 form showed consistently lower transcriptional activation than the wild-type L162 form.PubMed 19585164expression eqtl · directIn a small human cell study, Rudkowska et al. reported that carriers of the PPARA V162 allele had lower expression of PPARA and APOA1 after DHA or EPA:DHA exposure compared with L162 homozygotes. This supports a lower-expression-response score for G-containing genotypes while keeping certainty moderate to low.PubMed 15735069biomarker association · loose proxyThe Framingham Heart Study analysis reported that the L162V effect on triglyceride and apolipoprotein C-III depended on polyunsaturated fat intake: V162 carriers had higher triglycerides at low PUFA intake but not at high PUFA intake. This supports a context-dependent interpretation rather than a fixed disease-risk claim.

expression · GG

PPARA gene expression

Not used for pathway scoring

rs1800206 GG is associated with reduced PPARA gene expression.

PPARA rs1800206 is scored as a lower PPAR-alpha transcriptional-response tendency for G-containing genotypes, with stronger scoring for GG than CG.

Likely effectLower gene expression signal
Signal sizeSmall signal
Evidence supportLimited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs1800206 in PPARA and annotate it as a coding variant that can be missense in relevant transcripts. The common studied change is PPARA L162V, with the G allele corresponding to the V162 form in the cited functional studies.PubMed 19266045functional assay · loose proxyRudkowska et al. compared the L162 and V162 PPAR-alpha forms in HepG2 cell assays after omega-3 fatty acid treatment. Both forms responded to omega-3 fatty acids, but the V162 form showed consistently lower transcriptional activation than the wild-type L162 form.PubMed 19585164expression eqtl · directIn a small human cell study, Rudkowska et al. reported that carriers of the PPARA V162 allele had lower expression of PPARA and APOA1 after DHA or EPA:DHA exposure compared with L162 homozygotes. This supports a lower-expression-response score for G-containing genotypes while keeping certainty moderate to low.PubMed 15735069biomarker association · loose proxyThe Framingham Heart Study analysis reported that the L162V effect on triglyceride and apolipoprotein C-III depended on polyunsaturated fat intake: V162 carriers had higher triglycerides at low PUFA intake but not at high PUFA intake. This supports a context-dependent interpretation rather than a fixed disease-risk claim.

expression · CC

PPARA gene expression

Not used for pathway scoring

rs1800206 CC has no scored directional claim for PPARA gene expression.

PPARA rs1800206 is scored as a lower PPAR-alpha transcriptional-response tendency for G-containing genotypes, with stronger scoring for GG than CG.

Likely effectNo clear expression signal
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs1800206 in PPARA and annotate it as a coding variant that can be missense in relevant transcripts. The common studied change is PPARA L162V, with the G allele corresponding to the V162 form in the cited functional studies.PubMed 19266045functional assay · loose proxyRudkowska et al. compared the L162 and V162 PPAR-alpha forms in HepG2 cell assays after omega-3 fatty acid treatment. Both forms responded to omega-3 fatty acids, but the V162 form showed consistently lower transcriptional activation than the wild-type L162 form.PubMed 19585164expression eqtl · directIn a small human cell study, Rudkowska et al. reported that carriers of the PPARA V162 allele had lower expression of PPARA and APOA1 after DHA or EPA:DHA exposure compared with L162 homozygotes. This supports a lower-expression-response score for G-containing genotypes while keeping certainty moderate to low.PubMed 15735069biomarker association · loose proxyThe Framingham Heart Study analysis reported that the L162V effect on triglyceride and apolipoprotein C-III depended on polyunsaturated fat intake: V162 carriers had higher triglycerides at low PUFA intake but not at high PUFA intake. This supports a context-dependent interpretation rather than a fixed disease-risk claim.
rs4253778PPARA intronic signal3 claims · 9 study rows

biomarker tendency · CC

PPARA biomarker tendency

Not used for pathway scoring

rs4253778 CC is associated with increased PPARA biomarker tendency.

PPARA rs4253778 is scored as a weak tendency toward higher lipid biomarkers for C-containing genotypes, strongest for CC.

Likely effectHigher biomarker tendency
Signal sizeSmall signal
Evidence supportLimited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs4253778 in PPARA and list it as a genic downstream transcript and intron variant. This supports treating the variant as a possible regulatory marker rather than a protein-changing enzyme or transporter variant.PubMed 35363365biomarker association · close proxyOrtega-Melendez et al. studied rs4253778 and rs1800206 in women from Northeast Mexico. After adjustment for age and BMI, rs4253778 showed significant association with total cholesterol and LDL cholesterol, and the authors concluded that the C allele was associated with higher total cholesterol and LDL in that population.PubMed 34400988other · mismatchThe athlete-performance study reported a pooled gymnast genotype association, not a lipid or metabolic biomarker association. It is retained as loose context and not scored directionally for the PPARA biomarker claim.

biomarker tendency · CG

PPARA biomarker tendency

Not used for pathway scoring

rs4253778 CG is associated with increased PPARA biomarker tendency.

PPARA rs4253778 is scored as a weak tendency toward higher lipid biomarkers for C-containing genotypes, strongest for CC.

Likely effectHigher biomarker tendency
Signal sizeMinimal signal
Evidence supportLimited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs4253778 in PPARA and list it as a genic downstream transcript and intron variant. This supports treating the variant as a possible regulatory marker rather than a protein-changing enzyme or transporter variant.PubMed 35363365biomarker association · close proxyOrtega-Melendez et al. studied rs4253778 and rs1800206 in women from Northeast Mexico. After adjustment for age and BMI, rs4253778 showed significant association with total cholesterol and LDL cholesterol, and the authors concluded that the C allele was associated with higher total cholesterol and LDL in that population.PubMed 34400988other · mismatchThe athlete-performance study reported a pooled gymnast genotype association, not a lipid or metabolic biomarker association. It is retained as loose context and not scored directionally for the PPARA biomarker claim.

biomarker tendency · GG

PPARA biomarker tendency

Not used for pathway scoring

rs4253778 GG has no scored directional claim for PPARA biomarker tendency.

PPARA rs4253778 is scored as a weak tendency toward higher lipid biomarkers for C-containing genotypes, strongest for CC.

Likely effectNo clear biomarker tendency
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data place rs4253778 in PPARA and list it as a genic downstream transcript and intron variant. This supports treating the variant as a possible regulatory marker rather than a protein-changing enzyme or transporter variant.PubMed 35363365biomarker association · close proxyOrtega-Melendez et al. studied rs4253778 and rs1800206 in women from Northeast Mexico. After adjustment for age and BMI, rs4253778 showed significant association with total cholesterol and LDL cholesterol, and the authors concluded that the C allele was associated with higher total cholesterol and LDL in that population.PubMed 34400988other · mismatchThe athlete-performance study reported a pooled gymnast genotype association, not a lipid or metabolic biomarker association. It is retained as loose context and not scored directionally for the PPARA biomarker claim.

Common symptoms people report

  • difficulty tolerating fasting or long gaps between meals
  • sluggish fat-loss response despite reasonable structure
  • lipid markers that stay unimpressive despite effort
  • energy that feels less stable when carbs are lower

Biomarkers to validate

Triglycerides

Useful for checking whether fat-handling patterns may be under pressure.

ApoB

Adds particle-level context when lipid transport and fat metabolism overlap.

Fasting insulin

Helpful when lipid and glucose flexibility questions overlap.

Where DNA analysis helps

DNA helps show whether fat-oxidation pathways deserve more attention before assuming the issue is only calories or willpower. It is most useful when paired with lipid and glucose markers.

Example Insight

Your fat-oxidation pathway may have less flexibility than generic nutrition advice assumes.

Suggested validation: triglycerides and apoB.

What to do next

  • Check triglycerides and apoB before assuming fat metabolism is fine.
  • Compare fat-use questions with glucose and appetite markers rather than isolating one pathway.
  • Review PPARA together with PPARG and APOE when lipid handling patterns overlap.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages

PPARG

PPARG metabolism gene

APOE

APOE gene metabolism

Triglycerides

triglycerides and metabolic health

Fasting insulin

fasting insulin and metabolism

Glucose regulation pathway

glucose regulation pathway

Lipid transport pathway

lipid transport pathway

Genetic test for weight loss Europe

genetic test for weight loss Europe

Related symptom angle

Slow metabolism genetics

Browse the knowledge base

See the full index of gene guides, biomarker guides, pathway guides, symptoms, buyer pages, and common questions.